Pfizer Japan's R&D centre reborn as RaQualia
This article was originally published in Scrip
Some 18 months after announcing that it would close the facility, Pfizerhas spun out its former central research laboratories in Japan into a new stand-alone business which will develop and license a portfolio of compounds sourced from its former parent.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.